<![CDATA[By bioactivity-directed fractionation, phytochemical and cytotoxic studies of the seeds of Pachyrrhizus erosus L. resulted in the isolation of isoflavonoid-based compounds, one novel compound and eight known compounds, comprising the novel coumaronochromene, pachyrrhisomene {1}, the known pterocarpan, neodulin {2}, the known 3-arylcoumarin, pachyrrhizin {3}, the known isoflavonoid, dehydroneotenone {4}, five known rotenoids, rotenone {5}, l2a-hydroxyrotenone {6}, 12a-hydroxypachyrrhizone {7}, 12a-hydroxyerosone {8}, and 12a-hydroxymunduserone {9}. The identities of these compounds were elucidated or confirmed using combination of modern one- and two- dimensional NMR techniques, such as 1H-1H COSY, CSCMID, 1H-1H NOESY, and selective INEPT, as well as by comparison with published spectroscopic data. It is likely that the novel compound, pachyrrhisomene {1} is derived from the same biosynthetic intermediate as the pterocarpan, neodulin {2}. All of these compounds were evaluated for their anticancer potential in a battery of tumour cell lines, comprishing P-388 lymphocytic leukemia, KB-carcinoma of the nasopharynx, a multi-drug resistant variant of KB, KB-VI, and a number of human cancer cell lines derived from a variety of tumour types, namely fibrosarcoma, lung, colon, melanoma, and breast. Two compounds, rotenone {5} and 12a-hydroxyrotenone {6} were observed to exhibit potent but nonspecific activity.]]>
Copyrights © 1994
